These innovative compounds represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://jasperyjfs211567.bloggerbags.com/44718273/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide